

## Contents

<b>List of Contributors</b>	<b>XV</b>
<b>Preface</b>	<b>XIX</b>
<b>A Personal Foreword</b>	<b>XXI</b>

### **Part One Overview of Aspartic Acid Proteases 1**

<b>1</b>	<b>Introduction to the Aspartic Proteinase Family 3</b>
	<i>Ben M. Dunn</i>
1.1	Introduction 3
1.2	Sequence Alignment and Family Tree 4
1.3	Three-Dimensional Structure 5
1.4	Conferences and Progress 13
1.5	Exploration of the Active Sites of Aspartic Proteinase and Relation to Drug Discovery 15
	References 19
<b>2</b>	<b>Aspartic Proteases: Structure, Function, and Inhibition 23</b>
	<i>Jordan Tang</i>
2.1	Introduction 23
2.2	Structures of Aspartic Proteases 25
2.2.1	Aspartic Proteases of the Pepsin Family 25
2.2.2	Aspartic Proteases Involved in Intramembrane Proteolysis 28
2.3	Catalytic Mechanism and Substrate Specificity 28
2.3.1	Catalytic Mechanism of Aspartic Proteases of the Pepsin Family 28
2.3.2	Specificity of Aspartic Proteases of the Pepsin Family 29
2.3.3	Catalytic Mechanism of Intramembrane Aspartic Proteases 30
2.4	Zymogen Activation 31
2.5	Inhibition and the Development of Inhibitor Drugs 32
2.5.1	Inhibition by Mimicking the Catalytic Transition State 32
2.5.2	Inhibition Not Involving Transition-State Mimicking 36
2.6	Perspectives 36



2.7	Information Resource on Aspartic Proteases	38
	References	39
<b>3</b>	<b>Human Aspartic Proteinases</b>	<b>43</b>
	<i>John Kay and Daniel Bur</i>	
3.1	Introduction	43
3.2	Human Aspartic Proteinases	44
3.2.1	Pepsin(ogen)	44
3.2.2	(Pro)Gastricsin	48
3.2.3	(Pro)Renin	51
3.2.4	(Pro)Cathepsin D	53
3.2.5	(Pro)Cathepsin E	54
3.3	New Human Aspartic Proteinases	59
3.3.1	(Pro)Napsin A	59
3.3.2	(Pro)Napsin B	61
3.4	Concluding Remarks	64
	References	64
<b>4</b>	<b>Structure-Based Drug Design Strategies for Inhibition of Aspartic Proteinases</b>	<b>71</b>
	<i>Jon B. Cooper</i>	
4.1	Introduction	72
4.2	Associated Disease States	72
4.2.1	Hypertension	72
4.2.2	AIDS	73
4.2.3	Amyloid Disease	74
4.2.4	Candidiasis	76
4.2.5	Peptic Ulcer Disease	76
4.2.6	Neoplasia	77
4.2.7	Malaria	78
4.3	Development of Aspartic Proteinase Inhibitors	78
4.4	General Strategies for Design of Renin Inhibitors	80
4.4.1	Elaboration of the Transition-State Analogue	80
4.4.1.1	Statine Analogues	83
4.4.1.2	Aminoalcohols	83
4.4.1.3	Glycols	84
4.4.1.4	Phosphinic Acid Analogues	84
4.4.1.5	Fluoroketone Analogues and Implications for Catalysis	84
4.4.2	Optimizing Complementarity of the Inhibitor	85
4.4.3	Rigidification	86
4.4.4	Optimizing <i>In Vivo</i> Stability	88
4.5	Structural Studies of Renin Complexed with Inhibitors	88
4.5.1	The Role of Hydrogen Bonds in Inhibitor Recognition	89
4.5.2	Specificity	89
4.5.3	Recent Success with a Nonpeptide Renin Inhibitor	91
4.6	Structure-Based Drug Design for the HIV Proteinase	92



4.6.1	The Problem of Drug Resistance with HIV	95
4.7	Structure-Based Drug Design for Other Aspartic Proteinases	96
4.8	Possible New Leads from Macromolecular Inhibitor Complexes and Zymogen Structures	97
4.9	Conclusions	99
	References	99

## **Part Two HIV-1 Protease as Target for the Treatment of HIV/AIDS 107**

### **5 HIV-1 Protease: Role in Viral Replication, Protein–Ligand X-Ray Crystal Structures and Inhibitor Design 109**

*Irene T. Weber and Yuan-Fang Wang*

5.1	Introduction	109
5.2	HIV-1 and the AIDS Pandemic	110
5.2.1	HIV Genome and Life Cycle Define Targets for Antiviral Therapy	110
5.2.2	HIV Protease is Essential for Viral Maturation	112
5.2.3	Substrate Specificity of HIV-1 PR	113
5.2.4	X-Ray Crystal Structures of HIV-1 PR	113
5.2.5	Reaction Mechanism of HIV PR	115
5.3	PR Interactions with Peptidic Inhibitors and Design of First Antiviral Inhibitors	117
5.4	PR–Inhibitor Interactions Revealed in Atomic Resolution Structures	119
5.5	The Challenge of Drug Resistance in HIV	123
5.5.1	Structures of Protease Variants with Darunavir and Insight into the Emergence of Multidrug Resistance	124
5.5.2	Our Crystallographic Studies and Development of the Next Generation of PRs with Ghosh Research Group	126
5.6	Future Perspectives	129
	References	130

### **6 First-Generation HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS 139**

*Scott C. Virgil*

6.1	Introduction	139
6.2	Structure of HIV Protease	140
6.3	Design of Inhibitors	141
6.3.1	Saquinavir	143
6.3.2	Ritonavir	147
6.3.3	Indinavir	152
6.3.4	Nelfinavir	155
6.3.5	Amprenavir	157
6.4	Viral Resistance to First-Generation Protease Inhibitors	159
6.5	Perspectives	161
	References	162



<b>7</b>	<b>Second-Generation Approved HIV Protease Inhibitors for the Treatment of HIV/AIDS</b>	<b>169</b>
	<i>Arun K. Ghosh and Bruno D. Chapsal</i>	
7.1	Introduction	169
7.2	Second-Generation Protease Inhibitors	171
7.2.1	Lopinavir	171
7.2.2	Atazanavir	175
7.2.2.1	CTP-518: A Partially Deuterated Version of Atazanavir with Improved ADME Properties	179
7.2.3	Fosamprenavir	180
7.2.4	Tipranavir	181
7.2.5	Darunavir and Subsequent Investigational Bis-THF-Based Protease Inhibitors	187
7.2.5.1	Brecanavir (BCV, GW640385)	188
7.2.5.2	Novel Bis-THF-Based GS-8374	189
7.2.5.3	SPI-256	190
7.2.6	Recent Investigational Inhibitors	190
7.2.6.1	PL100	190
7.3	Conclusion	194
	References	195
 <b>8</b>	 <b>Darunavir, a New PI with Dual Mechanism: From a Novel Drug Design Concept to New Hope Against Drug-Resistant HIV</b>	 <b>205</b>
	<i>Arun K. Ghosh, Bruno D. Chapsal, and Hiroaki Mitsuya</i>	
8.1	Introduction	205
8.2	Molecular Insights from Protein–Ligand X-Ray Crystal Structures of Early PIs and Design of Novel PIs Inspired by Nature	207
8.3	Design of Novel Protease Inhibitors Containing Cyclic and Polycyclic Ether Templates	209
8.3.1	Further Optimization of Ligand Binding: Creation of the Bis-THF and Cp-THF Ligands	210
8.4	Development of PIs Based Upon Our “Backbone Binding Concept” to Combat Drug-Resistant HIV	213
8.4.1	Design Strategy to Maximize Backbone Hydrogen Bonding Throughout the Active Site	213
8.4.2	Structural Evidence of a Network of Hydrogen Bonding with Backbone Atoms	215
8.5	Antiviral Activities, Resistance Profiles of TMC 126 (20), and Relevance to “Backbone Binding Concept”	217
8.6	Selection of TMC114 and Its Subsequent Development to Darunavir	219
8.7	High-Resolution X-Ray Structure of Darunavir-Bound HIV-1 Protease	221
8.8	A Unique Dual Mode of Action: Darunavir also Inhibits Dimerization of HIV-1 Protease	224



8.9	Optically Active Synthesis of Bis-THF Ligand for Initial Clinical Studies and Beyond	224
8.10	Pharmacological Profile of Darunavir: ADME Properties	225
8.10.1	Absorption	226
8.10.2	Distribution	227
8.10.3	Metabolism and Excretion	227
8.11	Therapeutic Evaluation of DRV	228
8.11.1	Clinical Efficacy	228
8.11.2	Safety and Tolerability	230
8.11.3	Resistance Profile of Darunavir	231
8.11.4	Darunavir and the Previously Implausible Prospective of HIV Monotherapy	232
8.11.5	Clinical Use of Darunavir and Cost-Efficacy	234
8.12	Conclusion	234
	References	235
<b>9</b>	<b>Development of HIV-1 Protease Inhibitors, Antiretroviral Resistance, and Current Challenges of HIV/AIDS Management</b>	<b>245</b>
	<i>Hiroaki Mitsuya and Arun K. Ghosh</i>	
9.1	Introduction	245
9.2	Targeting the Viral Protease	246
9.3	The Role of PIs and the Challenges Faced by HAART	247
9.4	“Boosting”: A Critical Modification to the Clinical Efficacy of PIs	249
9.5	HIV-1 Variants Resistant to Conventional PIs	250
9.5.1	Primary and Secondary Mutations	250
9.5.2	Active Site Mutations	251
9.5.3	Nonactive Site Mutations	252
9.6	New Generation PIs with Activity against Drug-Resistant HIV-1	253
9.7	A Novel Modality of HIV-1 Protease Inhibition: Dimerization Inhibition	254
9.8	HIV-1 Resistance to Darunavir	255
9.9	When to Start HAART with Protease Inhibitors	257
9.10	Conclusions	258
	References	259
	<b>Part Three Renin as Target for the Treatment of Hypertension</b>	<b>263</b>
<b>10</b>	<b>Discovery and Development of Aliskiren, the First-in-Class Direct Renin Inhibitor for the Treatment of Hypertension</b>	<b>265</b>
	<i>Jeanette M. Wood and Jürgen Maibaum</i>	
10.1	Introduction	265
10.2	The History of Renin and Aliskiren	265
10.3	The Renin–Angiotensin–Aldosterone System	267
10.3.1	The Role of RAAS in Cardiovascular Disease	267



10.3.2	Biochemical Consequences of Different Modes of RAAS Blockade	269
10.4	History of the Renin Inhibitor Project in Ciba–Geigy/Novartis	269
10.5	New Concept Toward (P <sub>3</sub> –P <sub>1</sub> ) Topological Peptidomimetic Inhibitors	272
10.6	Early Preclinical Leads	274
10.6.1	The Tetrahydroquinoline Series	274
10.6.2	The “Phenoxy” Series: The Road to Aliskiren	276
10.6.3	Multiple Chemotype (S <sub>3</sub> –S <sub>1</sub> ) Topological Transition-State Analogues	279
10.7	Scalable Synthesis Development of Aliskiren	280
10.8	Properties of Aliskiren	282
10.8.1	Biochemical and Pharmacological Properties	282
10.8.2	Effects of Aliskiren in Animal Cardiovascular Disease Models	284
10.8.3	Absorption, Distribution, Metabolism, and Safety Properties of Aliskiren in Preclinical Models	285
10.8.4	Clinical Pharmacokinetics and Interactions with Other Drugs	286
10.8.5	Pharmacodynamic Effects of Aliskiren on Components of the RAAS	287
10.8.6	Clinical Safety Profile of Aliskiren	287
10.9	Clinical Efficacy of Aliskiren	288
10.9.1	Patients with Hypertension	288
10.9.2	End Organ Protection of Aliskiren in Patients with Diabetes, Chronic Renal Disease, and Heart Failure	289
10.10	Conclusions and Outlook	290
	References	291

## 11 Evolution of Diverse Classes of Renin Inhibitors Through the Years 297

*Colin M. Tice and Suresh B. Singh*

11.1	Introduction	297
11.2	Mechanism and Structural Biology of Renin	298
11.3	Screening and Animal Models	300
11.4	Peptidomimetic Renin Inhibitors	301
11.4.1	CGP-38560	301
11.4.2	Remikiren and Ciprokiren	304
11.4.3	Enalkiren and Zankiren	304
11.4.4	CI-992	305
11.5	Nonpeptidomimetic Renin Inhibitors	306
11.5.1	Aliskiren	306
11.5.2	Piperidines and Piperazines	308
11.5.3	Diaminopyrimidines	311
11.5.4	Alkylamines	312
11.6	Conclusions	313
	References	314



**Part Four  $\gamma$ -Secretase as Target for the Treatment of Alzheimer's Disease 325****12  $\gamma$ -Secretase: An Unusual Enzyme with Many Possible Disease Targets, Including Alzheimer's Disease 327***Johan Lundkvist and Urban Lendahl*

- 12.1 Introduction 328
- 12.2 Presenilin: From a Zymogen to the Subunit of a Complex Enzyme 329
- 12.3  $\gamma$ -Secretase: A Promiscuous Enzyme That Mediates Regulated Intramembrane Proteolysis 333
- 12.4 Structure of  $\gamma$ -Secretase 335
- 12.5 Mechanism of  $\gamma$ -Secretase 336
- 12.6 Pharmacology of  $\gamma$ -Secretase 337
- 12.7 Concluding Remarks 343
- References 343

**13  $\gamma$ -Secretase Inhibition: An Overview of Development of Inhibitors for the Treatment of Alzheimer's Disease 353***Christopher L. Hamblett, Sanjiv Shah, Richard Heidebrecht, Jr., and Benito Munoz*

- 13.1 Introduction 354
- 13.2 APP Genetics 356
- 13.3 Amyloid Cascade Hypothesis 358
- 13.3.1 Presenilin Genetics 358
- 13.4  $\gamma$ -Secretase Inhibitors: Compounds and Clinical Results 360
- 13.5 Notch-Sparing  $\gamma$ -Secretase Inhibitors: Compounds and Clinical Results 372
- 13.6  $\gamma$ -Secretase Modulators: Compounds and Clinical Results 374
- 13.7 Conclusion 379
- References 380

**Part Five  $\beta$ -Secretase as Target for the Treatment of Alzheimer's Disease 391****14 BACE: A (Almost) Perfect Target for Staving Off Alzheimer's Disease 393***Sukanto Sinha*

- 14.1 Introduction: APP Cloning,  $\alpha$ -Secretase Pathway, and  $\beta$ -Secretase Hypothesis 393
- 14.2 Cell Biology Evidence for  $\beta$ -Secretase 394
- 14.2.1  $\beta$ -Secretase Purification and Cloning 395
- 14.2.2 BACE Processing and Maturation 396
- 14.2.3 BACE Biochemistry 400
- 14.3 BACE-Deficient Mice: Effect on A $\beta$  Production 403
- 14.4 Other BACE Substrates 405
- 14.5 BACE Structure and BACE Inhibitors 406
- 14.6 Conclusions 408
- References 409



<b>15</b>	<b>The Discovery of <math>\beta</math>-Secretase and Development Toward a Clinical Inhibitor for AD: An Exciting Academic Collaboration</b>	<b>413</b>
	<i>Jordan Tang, Lin Hong, and Arun K. Ghosh</i>	
15.1	Introduction	413
15.2	Discovery of Memapsin 2 and Its Identification as $\beta$ -Secretase (by Jordan Tang)	414
15.2.1	Enzymatic Properties and Inhibition of Memapsin 2 (by Jordan Tang)	416
15.3	Design of the First Substrate-Based Inhibitors: A Remarkable Scientific Adventure Between Two Laboratories (by Jordan Tang and Arun Ghosh)	416
15.3.1	Leu-Ala Design Implementation at My Laboratory (by Arun Ghosh)	418
15.3.2	Exciting Results with the Leu-Ala Design (by Jordan Tang and Arun Ghosh)	420
15.4	Crystal Structure of Memapsin 2 and Binding of Inhibitors (by Lin Hong)	421
15.4.1	Memapsin 2 Structure	422
15.4.2	Memapsin 2 Interactions with Inhibitors	423
15.5	Evolution of Memapsin 2 Inhibitors (by Arun Ghosh)	424
15.5.1	Early Structure-Activity Studies	425
15.5.2	Structure-Based Design of Macrocyclic Inhibitors	428
15.5.3	Design and Development of Selective Memapsin 2 Inhibitors	429
15.5.4	Structure-Based Design of Diverse Structural Leads	431
15.5.5	Inhibitors with "Drug-Like" Features	433
15.6	Perspective	437
	References	438
<b>16</b>	<b>Peptidomimetic BACE1 Inhibitors for Treatment of Alzheimer's Disease: Design and Evolution</b>	<b>441</b>
	<i>Ulrich Iserloh and Jared N. Cumming</i>	
16.1	Introduction	441
16.2	Substrate-Based (Peptidic) Inhibitors	442
16.3	Peptidomimetic Statine and Homostatine Inhibitors	446
16.4	Hydroxyethylamine-Based Inhibitors	449
16.5	Other Peptidomimetics	460
16.6	Conclusions	465
	References	466
<b>17</b>	<b>Nonpeptide BACE1 Inhibitors: Design and Synthesis</b>	<b>481</b>
	<i>Derek C. Cole and Matthew G. Bursavich</i>	481
17.1	Introduction	481
17.2	Preliminary Peptidomimetic BACE1 Inhibitors	482
17.3	Acyl Guanidine-Based Inhibitors	484
17.4	Aminoimidazolone-Based Inhibitors	486



17.5	2-Aminopyridine and Pyrimidine-Based Inhibitors	486
17.6	Aminoimidazopyrimidine-Based Inhibitors	488
17.7	2-Aminoquinazoline-Based Inhibitors	490
17.8	Piperidine and Piperazine-Based Inhibitors	492
17.9	Other Miscellaneous Scaffolds	495
17.10	Conclusions	500
	References	500

## **Part Six Plasmepsins and Other Aspartic Proteases as Drug Targets 511**

### **18 The Plasmepsin Family as Antimalarial Drug Targets 513**

*Adam J. Ruben, Yoshiaki Kiso and Ernesto Freire*

18.1	Introduction	514
18.2	Plasmepsins <i>In Vivo</i>	514
18.2.1	Plasmepsin Function	515
18.2.2	Plasmepsins as Drug Design Targets	517
18.3	Plasmepsins <i>In Vitro</i>	518
18.4	Plasmepsin Family Structures	522
18.4.1	Structure-Based Insights into Plasmepsin Function	523
18.4.2	Activation	523
18.4.3	Quaternary Structure	523
18.5	Plasmepsin Inhibitors	528
18.6	Conclusions	535
	References	536

### **19 Plasmepsins Inhibitors as Potential Drugs Against Malaria: Starving the Parasite 549**

*Sandra Gemma*

19.1	Introduction	549
19.2	The Plasmepsin Family of Enzymes	550
19.3	Inhibitors of the Plasmepsin Family of Enzymes	552
19.4	Transition-State Isostere-Based Inhibitors	553
19.5	Nonpeptidic Inhibitors	561
19.6	“Double-Drugs”	564
19.7	Conclusions	565
	References	566

### **20 Fungal Aspartic Proteases as Possible Therapeutic Targets 573**

*Michel Monod, Peter Staib, Utz Reichard, and Olivier Jousson*

20.1	Introduction	574
20.2	Biochemical Properties of Fungal Aspartic Proteases (Table 20.1)	574
20.2.1	Secreted and Vacuolar Fungal Aspartic Proteases (Figure 20.1, Clades 3–6, 16, 19–21)	574
20.2.2	Barrierpepsin (Figure 20.1, Clade 9)	581
20.2.3	Yapsins (Figure 20.1, Clades 1, 2, 8, and 11)	582



20.3	Phylogeny of Fungal Aspartic Proteases	582
20.3.1	Aspartic Proteases in Ascomycete Yeasts (Subphylum Saccharomycotina) (Figure 20.2)	584
20.3.2	Aspartic Proteases in Filamentous Fungi (Mucorous Fungi, Basidiomycetes, and Filamentous Ascomycetes)	585
20.4	Production of Fungal Aspartic Proteases	585
20.5	Biological Functions of Aspartic Proteases in Fungi	588
20.5.1	Major Secreted Proteases	588
20.5.2	Vacuolar Aspartic Proteases	588
20.5.3	Barrierpepsin	589
20.5.4	Yapsins	589
20.5.5	Other Aspartic Protease Functions	590
20.6	Secreted Aspartic Proteases in Virulence of <i>C. albicans</i>	590
20.7	Functions of Aspartic Protease in <i>C. albicans</i> Virulence Processes	592
20.8	Secreted Aspartic Proteases in the Virulence of <i>Candida</i> Species Other Than <i>C. albicans</i>	593
20.9	Secreted Aspartic Proteases During Infection by Opportunistic Filamentous Fungi	594
20.10	Fungal Aspartic Proteases as Possible Drug Targets	594
20.11	Conclusions	596
	References	596

<b>Index</b>	607
--------------	-----